Rohit Sharma
Partner @ True Ventures
San Francisco, United States
Rohit Sharma is a partner at True Ventures. He began his career as founder and CTO of ONI Systems, which pioneered the use of optical switching and real-time signal processing technologies in optical networks. ONI Systems was acquired by Ciena, where Rohit served as SVP and CTO of Metro Networks Group.Rohit holds a bachelor’s degree inelectronics and communications engineering from India’s National Institute of Technology, Kurukshetra. He also holds Master of Science and Doctor of Philosophy degrees in electrical engineering from University of Alberta, Canada, where he endowed a professorship in digital communications in 2004. In 2013, he was awarded an honorary Doctorate of Science by the President of India at NITK’s 50th anniversary convocation.Rohit is fascinated by many aspects of innovation and technology. He believes all rabbit holes, especially across technology and society, are worth exploring. He is also a keen student of the many ways in which startups evolve into thriving companies. Rohit firmly believes that the “people part” of a startup is just as, if not more, critical to a company’s success than the technology piece of the business.
- Total investments:
- 40
- Last investment:
- Lead investor:
- 43%
Last updated:
For AI agents: llms.txt
Industries Rohit Sharma invests in
Stages Rohit Sharma invests in
Countries Rohit Sharma invests in
Round sizes
Contacts
| Type | Contact | Validation |
|---|---|---|
| Work email | ||
| Personal email | ||
| Work phone | ||
| Personal phone | ||
| Socials |
Round size
- Seed
- $1.2M–$7.9M
- Series A
- $8.7M–$20M
- Series B
- $24M–$60M
Investment Focus
Industry
- Robotics 7 (18%)
- Artificial Intelligence 6 (15%)
- Software 4 (10%)
- Biotechnology 4 (10%)
- Machine Learning 4 (10%)
Stage
- Seed 11 (28%)
- Series A 9 (23%)
- Series B 6 (15%)
- Series C 5 (13%)
- Series D 1 (3%)
Country
- United States 12 (30%)
- India 1 (3%)
- Canada 1 (3%)
- Israel 1 (3%)
- Finland 1 (3%)
Investments
| Company | Description | Round | Links |
|---|---|---|---|
Channel Robotics
|
Channel Robotics is a developer of AI-powered miniature robotic systems for advanced endoscopic surgery. | $4.6M / Seed / Jun 18, 2026 | |
Conifer
|
Conifer builds compact and modular powertrains to power everything that moves. | $20M / Seed / Apr 14, 2025 | |
Enveda Biosciences
|
Enveda Biosciences is a biotechnology company building new medicines from plants. It harnesses the complexity of the natural world to tackle today’s biggest healthcare challenges. With the help of the advancements in knowledge graphs, machine learning, and metabolomics, they discover the next generation of small molecules. Its technologiessystematize the discovery of small molecules and novel targets for complex diseases. By probing novel chemical space and mechanisms of action, they are breaking the status quo for challenging diseases with a need for effective treatments, such as fibrosis or neurodegeneration.Enveda, launched in 2019, is based in San Francisco, California. | $130M / Series C / Nov 21, 2024 | |
Basecamp Research
|
Basecamp Research is a market leader in mapping biodiversity for AI-based design of biological systems. We match and refine novel proteins for our partners' exact industrial, therapeutic or diagnostic applications using BaseGraph™, a new generation of AI design that is powered by the first-ever high-resolution map of global geneticbiodiversity. Understanding the full genetic, evolutionary, and environmental context of each protein allows Basecamp Research to design tailored proteins for specific applications without the need for expensive and time-consuming directed evolution campaigns. We're a team of explorers, scientists and policy experts driven by our ambition to protect and learn from nature's diversity, whilst delivering life-changing breakthroughs to those who need them most. | $60M / Series B / Oct 09, 2024 | |
|
Enveda Biosciences
|
Enveda Biosciences is a biotechnology company building new medicines from plants. It harnesses the complexity of the natural world to tackle today’s biggest healthcare challenges. With the help of the advancements in knowledge graphs, machine learning, and metabolomics, they discover the next generation of small molecules. Its technologiessystematize the discovery of small molecules and novel targets for complex diseases. By probing novel chemical space and mechanisms of action, they are breaking the status quo for challenging diseases with a need for effective treatments, such as fibrosis or neurodegeneration.Enveda, launched in 2019, is based in San Francisco, California. | $55M / Series B / Jun 14, 2024 | |
Ati Motors
|
Ati Motors is an all-electric autonomous industrial vehicle maker. | $10.6M / Series A / Jul 21, 2023 | |
|
Enveda Biosciences
|
Enveda Biosciences is a biotechnology company building new medicines from plants. It harnesses the complexity of the natural world to tackle today’s biggest healthcare challenges. With the help of the advancements in knowledge graphs, machine learning, and metabolomics, they discover the next generation of small molecules. Its technologiessystematize the discovery of small molecules and novel targets for complex diseases. By probing novel chemical space and mechanisms of action, they are breaking the status quo for challenging diseases with a need for effective treatments, such as fibrosis or neurodegeneration.Enveda, launched in 2019, is based in San Francisco, California. | $51M / Series B / Apr 20, 2023 | |
Scythe
|
Scythe Robotics is a robotics company that develops autonomous machines to tackle challenges in unstructured outdoor environments. Scythe aims to provide advanced and sustainable autonomous technology for maintaining off-road environments safely, effectively, and responsibly. Founded in 2018, Scythe is headquartered in Longmont, Colorado. | $42M / Series B / Jan 24, 2023 | |
|
Enveda Biosciences
|
Enveda Biosciences is a biotechnology company building new medicines from plants. It harnesses the complexity of the natural world to tackle today’s biggest healthcare challenges. With the help of the advancements in knowledge graphs, machine learning, and metabolomics, they discover the next generation of small molecules. Its technologiessystematize the discovery of small molecules and novel targets for complex diseases. By probing novel chemical space and mechanisms of action, they are breaking the status quo for challenging diseases with a need for effective treatments, such as fibrosis or neurodegeneration.Enveda, launched in 2019, is based in San Francisco, California. | $55M / Series B / Dec 21, 2022 | |
|
Basecamp Research
|
Basecamp Research is a market leader in mapping biodiversity for AI-based design of biological systems. We match and refine novel proteins for our partners' exact industrial, therapeutic or diagnostic applications using BaseGraph™, a new generation of AI design that is powered by the first-ever high-resolution map of global geneticbiodiversity. Understanding the full genetic, evolutionary, and environmental context of each protein allows Basecamp Research to design tailored proteins for specific applications without the need for expensive and time-consuming directed evolution campaigns. We're a team of explorers, scientists and policy experts driven by our ambition to protect and learn from nature's diversity, whilst delivering life-changing breakthroughs to those who need them most. | $19.9M / Series A / Dec 13, 2022 | |
| See all 40 investments → | |||
Co-Investors
About True Ventures
Founded in 2005, True Ventures is a Silicon Valley-based venture capital firm that invests in early-stage technology startups. With more than $3.8 billion under management, True provides seed and Series A financing to entrepreneurs in some of today's growing markets. With more than 40 team members including special advisors, operationsprofessionals, and founders-turned-investors, True represents one of the largest and most experienced teams dedicated to the ecosystem. The True team believes creativity flourishes when founders are supported fully and empowered to pursue brave ideas. To that end, the True Platform offers programs that inspire professional and personal growth. To date, True has helped more than 350 companies launch and scale their businesses, creating over 85,000 jobs worldwide. True was awarded Venture Firm of the Year by the National Venture Capital Association in 2018. To learn more, visit www.trueventures.com.
True Ventures Contacts
| Name | Phone | Socials | |
|---|---|---|---|
Amy Tusman
Executive Assistant
|
|||
Gus Coldebella
Partner
|
|||
Jeffrey Veen
Design Partner and Head of Platform
|
|||
|
Rohit Sharma
Partner
|
|||
Adam D'Augelli
Partner
|
Access 48,091 investors
822 industries, 177 countries. Updated daily. Emails and phones included.
Browse database — It's Free!
Find investors for your startup
Search 48,091 investors by industry and country. Emails and phones included.
Similar Investors
Featured in Investor Lists
Recommended lists
FAQ
What does Rohit Sharma invest in?
Rohit Sharma invests primarily in Robotics, Artificial Intelligence and Software startups, most often at Seed and Series A stage. Most of the 40 investments tracked by Shizune back companies in United States. The Investment Focus section breaks down every industry, stage and country in the portfolio.
What is Rohit Sharma's check size?
Rohit Sharma typically joins rounds of $1.2M–$7.9M at Seed, $8.7M–$20M at Series A and $24M–$60M at Series B. These ranges are 10th–90th percentile round sizes calculated from confirmed public funding rounds, so they are a realistic guide to the rounds Rohit Sharma participates in.
How do I contact Rohit Sharma?
Public channels for Rohit Sharma include LinkedIn, X (Twitter) and the website linked on this profile. For a verified work email and phone number, create a free Shizune account — contact data is searched across 20+ sources and validated before delivery, so your outreach lands in the right inbox.
When did Rohit Sharma last invest?
The most recent investment recorded for Rohit Sharma closed in Jun 2026. Shizune tracks 40 investments in total for this profile, including round sizes, stages and portfolio companies, all sourced from confirmed public funding rounds and refreshed monthly.
Is Shizune's investor data accurate?
Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Sep 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.
Contact your first 100 investors today
Find who invests in your industry, stage, and country. Download investor list with emails in 5 minutes.
Find investors — It's Free!
Continue with Google
Continue with LinkedIn
